scholarly journals HOMEOPATHIC MEDICINES-AAKASHMONI WILL BE THE BEST VACCINE AGAINST COVID-19: ENRICHING AGRICULTURE SCIENCE AND TECHNOLOGY COMMUNICATION MECHANISM APPLICATION ISSUES!

2020 ◽  
Vol 8 (11) ◽  
pp. 333-361
Author(s):  
Subhas Chandra Datta
Keyword(s):  
Low Dose ◽  
Case Reports ◽  
Science And Technology ◽  
Foliar Spray ◽  
Field Trials ◽  
Acacia Auriculiformis ◽  
Effective Vaccine ◽  
Relative Molecular Mass ◽  
Natural Defense ◽  
Communication Mechanism

Still now, no effective vaccine or treatment for the fifth endemic novel coronavirus COVID-19, forming endemic, is analogous to war, affecting our normal-, private- and professional- life, the planet economy, and also the communities. It is reported from the previous experiments, the homeopathic biomedicines; Aakashmoni or Acaciasides, or Acacia auriculiformis-extract, is being employed traditionally to beat various medical complications. Present pretreatment with ultra-high-diluted homeopathic biomedicine-Aakashmoni, prepared from the fruits of acacia A. Cunn, mixed with water at a particularly low dose, were applied by foliar spray once daily for 15 days @ 10 ml/plant, against present, root-knot-, leaf spot-, powdery mildew-, mosaic- and tukra- mulberry diseases, during a field trials and silkworms rearing. Pretreatment- investigations have confirmed that ultra-high-diluted homeopathic biomedicine Aakashmoni highly effective in ameliorating different mulberry diseases by inducing their natural defense-response against pathogens-infection and leaving no residual toxicity within the leaves to affect the expansion of silkworms also.  Presently, no appropriate antiviral drugs are discovered to treat COVID-19. So, to concur matters, “Four Confirmed-Suggestions for Vaccine and Clinical Trials with Homeopathic Biomedicines-Aakashmoni at an especially low dose, Against COVID-19 at by Boosting system for the development of Science and Technology Communication Mechanism Application Issues” forming the ‘Best Vaccine’, which not only shows the clinical, physical, chemical, biological and physiological effects but also on relative molecular mass, explaining the confirmation of mechanism and action of the homeopathic medicines supported scientific experimentations and proofs, and also the future clinical-scientists develop all aspects of clinical-case-reports globally by publishing with the sincere hope that the crisis of human civilization will soon be over and also the whole world may retain in normal forms by fighting against the COVID-19 war.

scholarly journals BIOMEDICINES-CINA AGAINST COVID-19: CONTROLLED PLANT DISEASES ENRICHED SCIENCE AND TECHNOLOGY COMMUNICATION GREEN ECONOMY

2020 ◽  
Vol 8 (9) ◽  
pp. 234-255 ◽  
Author(s):  
Subhas Chandra Datta
Keyword(s):  
Defense Response ◽  
Low Dose ◽  
Science And Technology ◽  
Foliar Spray ◽  
Plant Diseases ◽  
Green Economy ◽  
Economic Plant ◽  
Natural Defense ◽  
Medical Disorders ◽  
Artemisia Nilagirica

The economic-plant-mulberry is infected by different pathogens causing diseases and significantly reduces silk production. Though pesticides are the most effective means of control, but they are expensive and not environment friendly. On the other hand, the ongoing spread of the novel coronavirus, forming epidemic, affecting human civilizations, because recently, no appropriate antiviral drugs for effective treatments or vaccines against COVID-19. To meet the challenge, it is reported that the therapeutic value of traditional-, complementary- and alternative-biomedicines-Artemisia nilagirica, has been used for centuries, to overcome various medical disorders.  So, to concur with the situation, it will require new and more efficient solutions, technologies, and products. Present pretreatment with ultra-high-diluted biomedicines-Cina, prepared from the flowering meristems of Artemisia nilagirica (Clarke) pamp, mixed with water at an extremely low dose, were applied by foliar spray once daily for 15 days @ 10 ml/plant, against naturally occurring, root-knot-, leaf spot-, powdery mildew-, mosaic- and tukra- mulberry diseases, in field trials and silkworms rearing. Pretreatment-investigations have revealed that ultra-high-diluted-Cina, highly effective in ameliorating different mulberry-diseases by inducing their natural defense-response against pathogens-infection and leaving no residual-toxicity in the leaves to affect the growth of silkworms also. It can be concluded that the ultra-high-diluted, eco-friendly easily-available, easily applicable-Cina, at an extremely low dose, not only used as a potential-biomedical-drug against various plant-diseases, by inducing natural-defense- response, but also, it may be effective against COVID-19 for vaccinations and clinical trials by boosting the natural immune system for the improvement of Science and Technology communication cost-effectiveness green-economy and biodiversity conservations as well as bio-applications issues. And the future clinical-scientists develop all aspects of clinical-case-reports by publishing in the appropriate medical research archives, with the sincere hope that this crisis will soon be over and the whole world, may fight against the COVID-19 war, retaining normal forms of human civilizations globally.

scholarly journals ACACIA AURICULIFORMIS-EXTRACT SYNTHESIS PR-PROTEINS DEVELOPED POTENTIAL BIOMEDICINES-VACCINE AGAINST OKRA-DISEASES AND COVID-19: IMPROVED SCIENCE TECHNOLOGY COMMUNICATIONS BIO-ECONOMY APPLICATIONS

2020 ◽  
Vol 8 (10) ◽  
pp. 249-270 ◽  
Author(s):  
Subhas Chandra Datta
Keyword(s):  
Defense Response ◽  
Tap Water ◽  
Sodium Dodecyl ◽  
Foliar Spray ◽  
Post Treatment ◽  
Plant Diseases ◽  
Pr Proteins ◽  
Acacia Auriculiformis ◽  
Natural Defense ◽  
Pathogenesis Related Protein

The pandemic COVID19, effects on global health, educations, clinical research, human civilization, and the economy. So, it has been an urgency to develop proper vaccines against coronavirus. India emphasis on the most nutritious economically-important number-one-consumption-vegetable, okra, used in many human diseases, is naturally infected by different pathogens and significantly reduces production. Though pesticides are the most effective means of control, but they are expensive and toxic to the environment. So, it will require new and more efficient solutions, technologies, products, and methods. Present pre- and post-treatment with biomedicines; Acacia auriculiformis-extract, prepared from the funicles of Acacia auriculiformis A. Cunn., dissolved in sterile tap water at 1mg/10ml, were applied by foliar spray once daily for 15 days @ 10 ml/plant, against Root-Knot (RK), Yellow Vein Mosaic Virus (YVMV) and Okra Enation Leaf Curl Virus (OELCV) diseases of okra, (Abelmoschus esculentus L. Moench) cv.Ankur-40. The soluble root-proteins were separated by using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and were scanned with a recording densitometer electrophoretic scanner, measuring the molecular weight of proteins. Pre- and post-treatment with high-diluted-biomedicines; Acacia auriculiformis extract, were highly effective in reducing different okra-diseases by synthesis of new pathogenesis-related-protein (PR-proteins), inducing their natural defense-response against pathogens-infection and enhanced their growth as well as protein content of fruits and roots. The high-diluted-biomedicines;  Acacia auriculiformis extract, not only used as a potential-biomedical-drugs or vaccine against various plant-diseases, by synthesis of new PR-proteins, increasing natural-defense-response, but also, it may help for the preparation of a vaccine against COVID-19, by increasing immunity and enriching science and technology communications applications, cost-effectiveness and biodiversity conservations as well as bio-economy-applications issues, reviving human civilizations in the old form. And in near future okra may itself be a ‘Potential Biomedicine as well as Vaccine’ and world will return in normal form by defeating COVID-19.

scholarly journals Low-dose oral immunotherapy for walnut allergy with anaphylaxis: Three case reports

2021 ◽  
Author(s):  
Koki Sasamoto ◽  
Ken-ichi Nagakura ◽  
Sakura Sato ◽  
Noriyuki Yanagida ◽  
Motohiro Ebisawa
Keyword(s):  
Low Dose ◽  
Case Reports ◽  
Oral Immunotherapy ◽  
Dose Oral

scholarly journals SAT0078 SAFETY OF LOW DOSE METHOTREXATE (MTX) IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 974.2-974
Author(s):  
A. Gunay ◽  
A. Davidson ◽  
I. Colmegna ◽  
D. Lacaille ◽  
H. Loewen ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Adverse Events ◽  
Low Dose ◽  
Opportunistic Infections ◽  
Case Reports ◽  
Cross Sectional Study ◽  
Study Quality ◽  
Sectional Study ◽  
Cross Sectional ◽  
Immunodeficiency Virus

Background:Increased awareness of the efficacy of MTX in rheumatic disease is leading to more MTX use in patients from HIV endemic areas. While HIV related immunosuppression may contribute to improvement of some rheumatic diseases, immune reconstitution from highly active antiretroviral therapy (HAART) may lead to exacerbation or presentation of autoimmune disorders for which MTX therapy may be warranted. Most management guidelines for rheumatic disease do not address MTX use in the context of HIV.Objectives:To systematically review the published literature on the safety of using MTX ≤30 mg per week in HIV.Methods:We searched CINAHL, Embase, Global, MEDLINE and World of Science databases (Jan 1990 to May 2018) for terms including ‘methotrexate’ and ‘human immunodeficiency virus’. We also searched citations from review articles. Titles, abstracts or full manuscripts were screened independently by 2 reviewers to identify studies reporting HIV in patients taking MTX. Study quality was assessed using the McGill Mixed Methods Appraisal Tool (MMAT). Data was extracted on MTX and HIV adverse events (MTX toxicity, HIV viral load, CD4 count). Descriptive summaries are presented for studies providing outcomes in patients taking MTX ≤30 mg per week.Results:After removing duplicates and studies not meeting criteria or not providing sufficient information, 42 of the 2714 identified reports were included (1 clinical trial, 2 cohort, 1 cross-sectional study, 38 case reports/case series). Most reports (81%) originated from USA or Europe. Study quality was generally good with most studies fulfilling 50-100% of MMAT criteria. The randomized controlled trial (USA) assessing MTX on atherosclerotic disease in HIV showed that adverse events were more common in MTX versus placebo (12.8% vs 5.6%, p non-inferiority <0.05) and included infection, transient CD4 and CD8 drop, pulmonary toxicity, and death (1 attributed to MTX/HIV, 1 unrelated). One cohort study (South Africa) reported 43 RA patients on MTX who acquired HIV. In this cohort, RA generally improved despite only 5 individuals continuing MTX. No data on MTX adverse event rates was reported. One cohort study (USA) reported 13 HIV patients with myositis. One received MTX (with other immunosuppression) without MTX adverse effects but died due to AIDS. A cross-sectional study (France) of 43 HIV pts with autoimmune disease reported one patient on MTX (and other immunosuppression) developed an adverse event (cytopenia) compared to 5/33 patients not on MTX (cytopenia). The 38 case reports/series described 54 individuals with HIV receiving MTX. Of these studies, 27 (describing 42 subjects) reported on MTX adverse events and 35 (describing 46 subjects) reported on HIV adverse events. MTX adverse events developed in 29 subjects (hematologic 13, renal/hepatic 1, opportunistic infections 10, other events 2). HIV adverse events were noted in 23 subjects (Kaposi’s sarcoma 4, CD4 decrease 16, HIV viral titer increase 4). Five deaths were reported (2 infection, 1 infection and wasting, 2 HIV related deaths). Most subjects also received corticosteroids or other immunosuppressants including biologics.Conclusion:There remains limited data on the safety of low dose MTX in HIV. Surveillance for HIV is warranted for individuals on MTX who are at risk for acquiring HIV. Caution and careful monitoring for MTX toxicity, opportunistic infections and HIV state is suggested if MTX is used in the setting of HIV particularly if combined with other immunosuppression.References:[1] Clin Infectious Disease 2019:68[2] J Rheumatology 2014:41[3] Arthritis and Rheumatism 2003:49[4] Medicine 2017:96Acknowledgments :Funding from International League Against RheumatismMcGill University Global Health Scholar AwardsDisclosure of Interests:Alize Gunay: None declared, Anna Davidson: None declared, Ines Colmegna: None declared, Diane Lacaille: None declared, Hal Loewen: None declared, Michele Meltzer: None declared, Yewondwossen Mengistu: None declared, Rosie Scuccimarri: None declared, Zenebe Yirsaw: None declared, Sasha Bernatsky: None declared, Carol Hitchon Grant/research support from: UCB Canada; Pfizer Canada

scholarly journals Treatment of Cancer and Inflammation With Low-Dose Ionizing Radiation

Dose-Response ◽  
2017 ◽  
Vol 15 (1) ◽  
pp. 155932581769753 ◽  
Author(s):  
Shuji Kojima ◽  
Mitsutoshi Tsukimoto ◽  
Noriko Shimura ◽  
Hironobu Koga ◽  
Akishisa Murata ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Ulcerative Colitis ◽  
Bone Metastasis ◽  
Low Dose ◽  
Case Reports ◽  
Low Dose Radiation ◽  
X Ray ◽  
Radiation Hormesis ◽  
Irradiation Treatment ◽  
Dose Radiation

There is considerable evidence from experimental studies in animals, as well as from clinical reports, that low-dose radiation hormesis is effective for the treatment of cancer and ulcerative colitis. In this study, we present 3 case reports that support the clinical efficacy of low-dose radiation hormesis in patients with these diseases. First, a patient with prostate cancer who had undergone surgical resection showed a subsequent increase in prostate-specific antigen (PSA). His PSA value started decreasing immediately after the start of repeated low-dose X-ray irradiation treatment and remained low thereafter. Second, a patient with prostate cancer with bone metastasis was treated with repeated low-dose X-ray irradiation. His PSA level decreased to nearly normal within 3 months after starting the treatment and remained at the low level after the end of hormesis treatment. His bone metastasis almost completely disappeared. Third, a patient with ulcerative colitis showed a slow initial response to repeated low-dose irradiation treatment using various modalities, including drinking radon-containing water, but within 8 months, his swelling and bleeding had completely disappeared. After 1 year, the number of bowel movements had become normal. Interest in the use of radiation hormesis in clinical practice is increasing, and we hope that these case reports will encourage further clinical investigations.

scholarly journals A Literature Review of Painful Hashimoto Thyroiditis: 70 Published Cases in the Past 70 Years

2019 ◽  
Vol 4 (2) ◽  
Author(s):  
Carol Chiung-Hui Peng ◽  
Rachel Huai-En Chang ◽  
Majorie Pennant ◽  
Huei-Kai Huang ◽  
Kashif M Munir
Keyword(s):  
Medical Treatment ◽  
Total Thyroidectomy ◽  
Low Dose ◽  
Case Reports ◽  
Corticosteroid Injection ◽  
Oral Prednisone ◽  
Case Series ◽  
Hashimoto Thyroiditis ◽  
Upper Respiratory Tract ◽  
Dose Oral

Abstract Painful Hashimoto thyroiditis (pHT) is a rare diagnosis, and optimal treatment remains unclear. To better characterize pHT, PubMed, Embase, Scopus, and Web of Science indexes were searched for case reports or case series reporting pHT, published between 1951 and February 2019. Seventy cases reported in 24 publications were identified. Female predominance (91.4%) and a median age of 39.00 years (interquartile range, 32.50-49.75 years) were observed. Among reported cases, 50.8% had known thyroid disease (including Hashimoto thyroiditis, Graves disease, and seronegative goiters), 83.3% had positive antithyroid peroxidase antibodies, and 71.2% had antithyroglobulin antibodies. Most cases did not have preceding upper respiratory tract symptoms or leukocytosis. Ultrasound features were consistent with Hashimoto thyroiditis. Thyroid function at initial presentation was hypothyroid (35.9%), euthyroid (28.1%), or thyrotoxic (35.9%). Cases evolved into hypothyroidism (55.3%) and euthyroidism (44.7%), whereas none became hyperthyroid after medical treatment. Thyroid size usually decreased after medical treatment. Most cases were empirically treated as subacute thyroiditis with corticosteroids, levothyroxine, or nonsteroidal anti-inflammatory drugs. However, no therapy provided sustained pain resolution. In subgroup analysis, low-dose oral prednisone (&lt;25 mg/d) and intrathyroidal corticosteroid injection showed more favorable outcomes. Total thyroidectomy yielded 100% sustained pain resolution. Diagnosis of pHT is based on clinical evidence of Hashimoto thyroiditis and recurrent thyroid pain after medical treatment. The reference standard of diagnosis is pathology. Total thyroidectomy or intrathyroidal glucocorticoid injection should be considered if low-dose oral prednisone fails to achieve pain control.

scholarly journals Application of Low Doses of Ionizing Radiation in Medical Therapies

Dose-Response ◽  
2020 ◽  
Vol 18 (1) ◽  
pp. 155932581989573 ◽  
Author(s):  
Jerry M. Cuttler
Keyword(s):  
Ionizing Radiation ◽  
Low Dose ◽  
Medical Profession ◽  
Case Reports ◽  
Damage Control ◽  
Bone Sarcoma ◽  
High Rate ◽  
X Rays ◽  
The Public ◽  
Internal Sources

The discovery of X-rays and radioactivity in 1895/1896 triggered a flood of studies and applications of radiation in medicine that continues to this day. They started with imaging fractures/organs and progressed to treating diseases by exposing areas to radiation from external and internal sources. By definition, low-dose treatments stimulate damage control (or adaptive protection) systems that remedy diseases. Publications are identified on low-dose ionizing radiation (LDIR) therapies for different cancers, infections, inflammations, and autoimmune and neurodegenerative diseases. The high rate of endogenous DNA damage, due to leakage of oxygen from aerobic metabolism, and the damage control systems that deal with this are discussed. Their stimulation and inhibition by radiation are described. The radium dial painter studies revealed the radium ingestion threshold for malignancy and the dose threshold for bone sarcoma. The radiation scare that misled the medical profession and the public is a barrier to LDIR therapies. Many studies on nasal radium irradiation demonstrated that children are not unduly radiation sensitive. Omissions in the medical textbooks misinform physicians about the effects of LDIR therapy, which blocks clinical trials to determine optimal doses, efficacy, and thresholds for onset of harm. Information from many recent case reports on LDIR therapies, including successes with radon therapy, is provided.

scholarly journals Slow Dose Ketamine — A New Technique

1980 ◽  
Vol 8 (3) ◽  
pp. 359-361 ◽  
Author(s):  
M. H. Sher
Keyword(s):  
Regional Anaesthesia ◽  
Low Dose ◽  
Case Reports ◽  
New Technique ◽  
Loss Of Consciousness ◽  
Dose Infusion ◽  
A New Technique ◽  
Surgical Operations

A technique using a very low dose infusion of ketamine to provide intense analgesia without loss of consciousness as an alternative to general or regional anaesthesia during selected surgical operations is described and illustrated with three case reports.

scholarly journals Candida albicansEpididymo-Orchitis and Fungemia in a Patient with Chronic Myelogenous Leukemia

1996 ◽  
Vol 7 (5) ◽  
pp. 332-334
Author(s):  
Mark Pimentel ◽  
Lindsay E Nicolle ◽  
Salman Qureshi
Keyword(s):  
Amphotericin B ◽  
Chronic Myelogenous Leukemia ◽  
Low Dose ◽  
Case Reports ◽  
Myelogenous Leukemia ◽  
Current Case ◽  
Characteristic Features ◽  
Immunocompromised State ◽  
Intravenous Amphotericin ◽  
Ultrasonographic Appearance

The fourth reported case of candidal epididymo-orchitis in the literature and the first reported case successfully cured with only low dose amphotericin B is described. A 75-year-old male with chronic myelogenous leukemia presented with acute testicular and epididymal swelling and pain. Subsequent investigations suggested the diagnosis of epididymo-orchitis due toCandida albicans. This was successfully treated with intravenous amphotericin B (total dose of 500 mg). Based on the three previous case reports and the current case several characteristic features that increased the suspicion of this entity were identified. These features include an immunocompromised state, candiduria, specific epididymal ultrasonographic appearance, as well as typical clinical features of epididymo-orchitis.

Sign in / Sign up

Export Citation Format

Share Document